PET imaging of brain cancer with positron emitter-labeled liposomes

Oku, Naoto; Yamashita, Mina; Katayama, Yurie; Urakami, Takeo; Hatanaka, Kentaro; Shimizu, Kosuke; Asai, Tomohiro; Tsukada, Hideo; Akai, Shuji; Kanazawa, Hiroaki

doi:10.1016/j.ijpharm.2010.10.001

Cited by 53 publications

(31 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, it is generally observed that the presence of targeting ligands over the liposome surface improves the uptake of vesicles by target cancer cells and increases their retention time within tumors. 231,233,239,247,253 In gliomas, angiogenesis seems to be the preferable target area for diagnosis of this cancer. Angiogenesis, the formation of new vessels, is a key process for glioma survival and growth.…”

Section: Design Of Liposomal Drug-delivery Systems For Glioma Diagnosismentioning

confidence: 99%

“…MRI of endoglin-target liposomes was able to demonstrate tumor 231 In the same way, PET of Ala-Pro-ArgPro-Gly peptide-targeted liposomes was able specifically to image the different structure of glioma vessels. 247 Also, liposome-targeted delivery of contrast agents containing antibodies to GFAP and the extracellular loop of Cx43 on its surface that selectively bound to brain-reactive astrocytes and faster-migrating glioma cells has been developed. 239 Also developed have been PEGylated liposomes containing VEGF antibody on the surface, increasing the distribution and efficacy of the delivery of liposomes to glioma.…”

Section: Design Of Liposomal Drug-delivery Systems For Glioma Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Vieira

Gamarra

2016

IJN

350

238

View full text Add to dashboard Cite

This review summarizes articles that have been reported in literature on liposome-based strategies for effective drug delivery across the blood–brain barrier. Due to their unique physicochemical characteristics, liposomes have been widely investigated for their application in drug delivery and in vivo bioimaging for the treatment and/or diagnosis of neurological diseases, such as Alzheimer’s, Parkinson’s, stroke, and glioma. Several strategies have been used to deliver drug and/or imaging agents to the brain. Covalent ligation of such macromolecules as peptides, antibodies, and RNA aptamers is an effective method for receptor-targeting liposomes, which allows their blood–brain barrier penetration and/or the delivery of their therapeutic molecule specifically to the disease site. Additionally, methods have been employed for the development of liposomes that can respond to external stimuli. It can be concluded that the development of liposomes for brain delivery is still in its infancy, although these systems have the potential to revolutionize the ways in which medicine is administered.

show abstract

Section: Design Of Liposomal Drug-delivery Systems For Glioma Diagnosismentioning

confidence: 99%

Section: Design Of Liposomal Drug-delivery Systems For Glioma Diagnosismentioning

confidence: 99%

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Vieira

Gamarra

2016

IJN

350

238

View full text Add to dashboard Cite

show abstract

“…In contrast, the liposomes easily entered into the site of the glioma, because of the lack of a functional BBB. In addition, the smallest tumor imaged by the liposomes was only 1 mm in width 70) (Fig. 2).…”

Section: Liposomal Traffic In the Brainmentioning

confidence: 98%

Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases

Oku

2017

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

Liposomes have been widely used as drug carriers in the field of drug delivery systems (DDS), and they are thought to be ideal nano-capsules for targeting DDS after being injected into the bloodstream. In general, DDS drugs meet the needs of aged and super-aged societies, since the administration route of drugs can be changed, the medication frequency reduced, the adverse effects of drugs suppressed, and so on. In fact, a number of liposomal drugs have been launched and used worldwide including liposomal anticancer drugs, and these drugs have appeared on the market owing to various innovations in liposomal DDS technologies. The accumulation of long-circulating liposomes in cancer tissue is driven by the enhanced permeability and retention (EPR) effect. In this review, liposome-based targeting DDS for cancer therapy is briefly discussed. Since cancer angiogenic vessels are the ideal target of drug carriers after their injection and are critical for cancer growth, damaging of these neovessels has been an approach for eradicating cancer cells. Also, the usage of liposomal DDS for the treatment of ischemic stroke is possible, since we observed that PEGylated liposomes accumulate in the site of cerebral ischemia in transient middle cerebral artery occlusion (t-MCAO) model rats. Interestingly, liposomes carrying neuroprotectants partly suppress ischemia/reperfusion injury of these model rats, suggesting that the EPR effect also works in ischemic diseases by causing an increase in the permeability of the blood vessel endothelium. The potential of liposomal DDS against life-threatening diseases might thus be attractive for supporting long-lived societies.

show abstract

“…42 Liposomes are phospholipid bilayer microspheres which can encapsulate both hydrophilic and hydrophobic compounds in the aqueous core. [52][53][54] Micelles, such as poly (lactic-co-glycolic acid) (PLGA), 55 poly (butyl cyanoacrylate) (PBCA), 56 and poly ("-caprolactone), (PCL), [57][58][59][60] are hydrophobic core compositions coated with surface-active agents such as polyethylene glycol (PEG) and dextran. These polymeric micelles self-assemble to form a lipophilic core for hydrophobic drug delivery.…”

Section: Np-based Platformsmentioning

confidence: 99%

The Application of Nanomaterials in Diagnosis and Treatment for Malignant Primary Brain Tumors

Liang

Fang

2014

NANO

View full text Add to dashboard Cite

Malignant primary brain tumors have a very high morbidity and mortality. Even though enormous advances have been made in primary brain tumor management, in the case of malignant primary brain tumors, current diagnostic strategies cannot identify exact in¯ltrating margins, surgery alone cannot achieve total mass resection, and adjuvant therapies cannot improve survivals. Therefore, there is an urgent need to explore novel strategies to diagnose and treat such in¯ltrating brain tumors. Nanomaterials, particularly zero-dimensional and one-dimensional platforms, can carry various compounds such as contrast agents, anticancer drugs and genes into brain tumor cells speci¯cally. Thus, contrast agent-based nanomaterials can selectively present in¯ltrating tumor outlines, while anticancer agent-based nanomaterials can speci¯cally kill malignant tumor cells. In addition, dual-targeting nanomaterials, multifunctional nanocarriers, theranostic nanovehicles as well as convection-enhanced delivery technology hold promise to increase drug accumulation in tumor tissues, which could largely improve anticancer e±cacy. In this review, we will mainly focus on the application of nanomaterials in preoperative diagnosis, intraoperative diagnosis and adjuvant treatment for malignant primary brain tumors.

show abstract

PET imaging of brain cancer with positron emitter-labeled liposomes

Cited by 53 publications

References 33 publications

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases

The Application of Nanomaterials in Diagnosis and Treatment for Malignant Primary Brain Tumors

Contact Info

Product

Resources

About

PET imaging of brain cancer with positron emitter-labeled liposomes

Cited by 53 publications

References 33 publications

Getting into the brain: liposome-based strategies for effective drug delivery across the blood&ndash;brain barrier

Getting into the brain: liposome-based strategies for effective drug delivery across the blood&ndash;brain barrier

Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases

The Application of Nanomaterials in Diagnosis and Treatment for Malignant Primary Brain Tumors

Contact Info

Product

Resources

About

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier